Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cardiorenal Medicine|January 19, 2018
Eicosapentaenoic Acid as a Potential Therapeutic Approach to Reduce Cardiovascular Risk in Patients with End-Stage Renal Disease on Hemodialysis: A ReviewKenneth M Borow, R Preston Mason, Krishnaswami VijayaraghavanAtherosclerosis|August 9, 2015
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosisKenneth M Borow, John R Nelson, R Preston MasonCirculation Research|July 19, 2019
Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart FailureKenneth M Borow, Alex Yaroshinsky, Barry Greenberg, et al.Pediatrics|February 13, 2021
Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in ChildrenAllison Ross Eckard, Kenneth M Borow, Elizabeth H Mack, et al.JTCVS Open|January 11, 2024
Prospective randomized controlled trial of the safety and feasibility of a novel mesenchymal precursor cell therapy in hypoplastic left heart syndromeRachel E Wittenberg, Kimberlee Gauvreau, Jonah Leighton, et al.European Journal of Heart Failure|November 27, 2024
Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HFEmerson C Perin, Kenneth M Borow, Timothy D Henry, et al.Circulation Research|July 8, 2015
A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart FailureEmerson C Perin, Kenneth M Borow, Guilherme V Silva, et al.Journal of the American College of Cardiology|March 1, 2023
Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart FailureEmerson C Perin, Kenneth M Borow, Timothy D Henry, et al.Journal of the American College of Cardiology|September 2, 2017
Optimizing Cholesterol Treatment in Patients With Muscle ComplaintsRobert S Rosenson, Steven Baker, Maciej Banach, et al.Pageof 1